As of today (2026-07-02), the Forward Annual Dividend Yield of Precision BioSciences is 0.00%.
As of today (2026-07-02), the Trailing Annual Dividend Yield of Precision BioSciences is 0.00%.
STU:PBS0's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.45 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Precision BioSciences Forward Dividend Yield % Related Terms
STU:PBS0 vs NBP, HUMA, ORMP: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Precision BioSciences's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precision BioSciences Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Precision BioSciences's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Precision BioSciences's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Precision BioSciences (STU:PBS0) has a Forward Dividend Yield % of 0.00% as of Jul. 02, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Precision BioSciences and its competitors. According to the industry distribution chart, Precision BioSciences ranks #999999 out of 147 companies in the Biotechnology industry.
Is Precision BioSciences' Forward Dividend Yield % too high?
Precision BioSciences' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Precision BioSciences ranks #999999 out of 147 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Precision BioSciences has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Precision BioSciences' Forward Dividend Yield % compare to NBP and HUMA?
According to the Biotechnology industry distribution chart, Precision BioSciences ranks #999999 out of 147 companies for Forward Dividend Yield %. This places Precision BioSciences in the lower half of its industry. The industry median Forward Dividend Yield % is 1.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.45, based on 147 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Precision BioSciences and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Precision BioSciences's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precision BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Precision BioSciences (STU:PBS0) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.59, compared to a current price of €6.97 — trading 338.4% above its estimated fair value. The current Forward Dividend Yield % is 0.00%. Precision BioSciences' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Precision BioSciences (STU:PBS0), the current Forward Dividend Yield % is 0.00% as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precision BioSciences (STU:PBS0) Overvalued in 2026?
Based on GuruFocus' analysis, Precision BioSciences stock appears to be overvalued.
The current stock price of €6.97 is trading 338.4% above its estimated GF Value™ of €1.59.
GuruFocus considers Precision BioSciences to be Significantly Overvalued.
Key valuation signals for STU:PBS0:
Forward Dividend Yield %: 0.00%
GF Value™: €1.59 vs. price of €6.97 (338.4% above fair value)
No single metric tells the full story. See the STU:PBS0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
44GF Score
Get the complete analysis for STU:PBS0
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PBS0 has been successfully added to your 